Oncolytics Biotech, Inc. (ONCY)
0.9232
0.00 (0.00%)
USD |
NASDAQ |
Jun 25, 16:00
0.9232
0.00 (0.00%)
After-Hours: 20:00
Oncolytics Biotech Research and Development Expense (Quarterly) : 4.552M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 4.552M |
| December 31, 2025 | -0.7839M |
| September 30, 2025 | 5.081M |
| June 30, 2025 | 1.916M |
| March 31, 2025 | 2.846M |
| December 31, 2024 | 3.255M |
| September 30, 2024 | 4.872M |
| June 30, 2024 | 3.265M |
| March 31, 2024 | 4.089M |
| December 31, 2023 | 3.420M |
| September 30, 2023 | 4.332M |
| June 30, 2023 | 2.756M |
| March 31, 2023 | 2.616M |
| December 31, 2022 | 3.566M |
| September 30, 2022 | 2.816M |
| June 30, 2022 | 2.509M |
| March 31, 2022 | 2.928M |
| December 31, 2021 | 2.919M |
| September 30, 2021 | 2.602M |
| June 30, 2021 | 2.609M |
| March 31, 2021 | 2.179M |
| December 31, 2020 | 3.117M |
| September 30, 2020 | 2.892M |
| June 30, 2020 | 1.804M |
| March 31, 2020 | 1.881M |
| Date | Value |
|---|---|
| December 31, 2019 | 2.043M |
| September 30, 2019 | 1.257M |
| June 30, 2019 | 2.549M |
| March 31, 2019 | 2.296M |
| December 31, 2018 | 2.278M |
| September 30, 2018 | 1.342M |
| June 30, 2018 | 1.708M |
| March 31, 2018 | 2.419M |
| December 31, 2017 | 1.863M |
| September 30, 2017 | 1.480M |
| June 30, 2017 | 2.226M |
| March 31, 2017 | 1.693M |
| December 31, 2016 | 2.602M |
| September 30, 2016 | 1.445M |
| June 30, 2016 | 1.340M |
| March 31, 2016 | 1.831M |
| December 31, 2015 | 1.694M |
| September 30, 2015 | 1.786M |
| June 30, 2015 | 1.895M |
| March 31, 2015 | 2.196M |
| December 31, 2014 | 2.206M |
| September 30, 2014 | 3.256M |
| June 30, 2014 | 3.277M |
| March 31, 2014 | 3.577M |
| December 31, 2013 | 4.422M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Replimune Group, Inc. | 52.87M |
| Arrowhead Pharmaceuticals, Inc. | 167.38M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 153.96M |
| Anixa Biosciences, Inc. | 1.258M |